title: [Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease].
abstract: BACKGROUND
  The pathogenesis of Still's disease is best elucidated for the better recognition of the involvement of Many pro-inflammatory cytokines in the genesis of this condition. Publications have reported the contribution beneficial for certain biotherapeutics, such as anti-TNFa, the anti-CD20 or antagonists of interleukine1 (IL-1) tested successfully in the treatment of systemic Juvenile idiopathic arthritis (Still's disease the child), the tocilizumab is a humanized monoclonal antibody directed against the receptor for interleukin-6 and is beginning to be reported as effective in some refractory cases of Still's disease in adults.
  
  
  METHODS
  We report two young patients with Still's disease in adults with refractory early and prolonged remission after the first infusion tocilizumab.
  
  
  CONCLUSIONS
  The tocilizumab can be used in patients MSA with refractory after failure or intolerance conventional treatments.
authors.affiliation: Département de médecine interne-B, hôpital Militaire d'Instruction Med-V, Rabat, Maroc. sekkach@hotmail.com
authors.forename: Youssef
authors.initials: Y
authors.lastname: Sekkach
authors.forename: Mohamed
authors.initials: M
authors.lastname: Elqatni
authors.forename: Abdessadek El
authors.initials: AE
authors.lastname: Khattabi
authors.forename: Jamal
authors.initials: J
authors.lastname: Fatihi
authors.forename: Salaheddine
authors.initials: S
authors.lastname: Hammi
authors.forename: Mohamed
authors.initials: M
authors.lastname: Badaoui
authors.forename: Naoual
authors.initials: N
authors.lastname: Elomri
authors.forename: Fadoua
authors.initials: F
authors.lastname: Mekouar
authors.forename: Taoufik
authors.initials: T
authors.lastname: Amezyane
authors.forename: Ali
authors.initials: A
authors.lastname: Abouzahir
authors.forename: Driss
authors.initials: D
authors.lastname: Ghafir
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D012074:Remission Induction; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D055815:Young Adult; D000093242:Interleukin-6 Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab